Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline

CorMedix (CRMD) heads into its Q3 2026 report with the numbers pointing the wrong way: analysts expect a quarterly loss of $0.09 per share and a 49.7% year-over-year revenue decline.

The setup offers little beat-side support. CRMD carries an Earnings ESP of -44.44%, meaning the most recent analyst estimates sit well below the consensus figure. That negative reading, paired with a Zacks Rank #3 (Hold), leaves the stock outside the profile Zacks associates with likely earnings beats.

The peer comparison sharpens the contrast. Coherus Oncology also shows a negative Earnings ESP, at -1.54%, yet it holds a Zacks Rank #2 (Buy). Interpretation: Coherus Oncology's ESP gap is far narrower than CRMD's, and its better rank suggests a less lopsided estimate picture heading into its own report.

Interpretation of the data: a revenue drop near 50% is a steep comparison hurdle, and the -44.44% ESP implies recent estimate revisions are skewing bearish rather than bullish. Neither metric guarantees a miss, but both argue against positioning for an upside surprise.